Skip to main content

Table 5 Comparison of ONCHOSIM and EPIONCHO with respect to estimated duration of treatment that is needed to bring mf prevalence below the provisional operational threshold for treatment interruption followed by commencement of surveillance (pOTTIS) of 1.4 %, measured just before what would be the next treatment round, and the estimated duration of treatment needed to drive the parasite population to local elimination in the absence of further treatment (allowing for the slow natural extinction in the absence of further interventions)

From: Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis

Approximate initial mf prevalence (%) in the population aged ≥ 5 years

Coverage (%)

Treatment duration needed to bring the 12-month or 6-month post-treatment mf prevalence below pOTTIS (years)

Treatment duration needed to drive the parasite population irreversibly to extinction in the absence of further treatment (years)

ONCHOSIM

EPIONCHO

ONCHOSIM

EPIONCHO

Annual treatment

    

 51

50

18

17

12

>25

 

65

14

15

8

23

 

80

12

12

6

21

 62

50

21

24

14

>25

 

65

16

20

10

>25

 

80

14

17

8

>25

 81

50

>25

>25

>25

>25

 

65

21

>25

18

>25

 

80

17

>25

15

>25

 87

50

>25

>25

>25

>25

 

65

25

>25

>25

>25

 

80

20

>25

20

>25

 91

50

>25

>25

>25

>25

 

65

>25

>25

>25

>25

 

80

23

>25

>25

>25

Biannual treatment

    

 51

50

12.5

12

6

21

 

65

10

11

4.5

20

 

80

8

10

4

19.5

 62

50

14

17

8.5

>25

 

65

11

16

6

>25

 

80

9.5

10

5

>25

 81

50

18.5

>25

17

>25

 

65

13.5

>25

12

>25

 

80

12

>25

10

>25

 87

50

22.5

>25

24

>25

 

65

15.5

>25

16.5

>25

 

80

13.5

>25

14

>25

 91

50

>25

>25

>25

>25

 

65

17

>25

21

>25

 

80

14.5

>25

18

>25

  1. Results are shown for different settings, varying with respect to the pre-control mf prevalence in the population aged ≥ 5 years, and for several treatment scenarios, varying with respect to the treatment frequency and achieved coverage (defined as the percentage of people who receive treatment in the total population)